About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
L
Unmet Needs in MF Treatment
By
Lindsay Rein
2 Videos
367 views
May 16, 2023
0 Comments
Login to view comments.
Click here to Login
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Related Content
AUTOPLAY
ON
27:37
Indy Hematology Review
Review of Myeloproliferative Neoplasms
Feat.
A. Tefferi
24:08
Indy Hematology Review
Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…
Feat.
A. Tefferi
18:04
Ruben Mesa
Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…
21:52
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Imp…
Feat.
D. Tremblay
31:43
Indy Hematology Review
Myelofibrosis: Chronic and Blast Phase - 2023 Algorithms for Risk St…
Feat.
A. Tefferi
24:35
Indy Hematology Review
Current Approaches in the Treatment of Myeloproliferative Neoplasms
Feat.
A. Tefferi
10:02
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of MPNs - Highlights & Key Take…
Feat.
R. Mesa
09:27
ASH 2022 Conference Coverage
MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…
Feat.
M. McMullin
12:18
Fred Hutchinson Cancer Center
Management of MPNs for the Community Oncologist
Feat.
H. Deeg
16:25
Northwestern Medicine Oncology and Hematology
Diagnosis and Goals of Therapy in PV
Feat.
B. Stein
12:07
Douglas Tremblay
Monitoring Patients With MF: When to Switch Treatment
11:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
2024 Updates in Myeloproliferative Neoplasms
Feat.
E. Hexner
24:48
Indy Hematology Review
2024 Updates on Myelofibrosis and Systemic Mastocytosis
Feat.
R. Rampal
17:51
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies
Chronic GVHD: A Case-Based Discussion
Feat.
L. Perry
15:31
Icahn School of Medicine at Mount Sinai
Myelofibrosis Treatment Options Beyond the JAK/STAT Pathway
Feat.
M. Kremyanskaya
51:20
Jerry Spivak
Polycythemia Vera: Disease Overview, Treatment Landscape, and Curren…
53:01
PleXus Communications
Changing Pharmacological Paradigms for Higher-Risk Myelofibrosis
Feat.
R. Rampal
11:09
Jeanne Palmer
Management of Clinical Manifestations in Myelofibrosis
15:41
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Addressing Anemia in Myelofibrosis
Feat.
S. Oh
17:34
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Novel Non-JAK Inhibitor Therapies for Myelofibrosis
Feat.
J. Mascarenhas
